CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.92B, above the global median of $1.15B
- PositionProfit margin is 46.8%, higher than 95% of its Biotechnology peers (median -45.7%)
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
1.64BEUR1.92B · vs all stocks (USD)
Trailing P/E
3.18xvs Biotechnology peers
Revenue (TTM)
1.04BEUR1.22B · vs all stocks (USD)
Profit Margin
46.83%vs Biotechnology peers
52-Week Change
-9.84%vs all stocks
Market Capitalization
1.64BEUR1.92B · vs all stocks (USD)
Enterprise Value
-1.39BEUR-1.63B · vs all stocks (USD)
Trailing P/E
3.18xvs Biotechnology peers
Forward P/E
-6.03xvs Biotechnology peers
PEG Ratio
-0.0291xvs Biotechnology peers
Price to Sales (TTM)
1.49xvs Biotechnology peers
Price to Book (MRQ)
0.4802xvs Biotechnology peers
Enterprise to Revenue
-1.33xvs Biotechnology peers
Enterprise to EBITDA
-2.10xvs Biotechnology peers
Profit Margin
46.83%vs Biotechnology peers
Operating Margin
-982.92%vs Biotechnology peers
Return on Assets (TTM)
10.66%vs Biotechnology peers
Return on Equity (TTM)
16.26%vs Biotechnology peers
Revenue (TTM)
1.04BEUR1.22B · vs all stocks (USD)
Revenue per Share (TTM)
15.84EURUpdated Aug 21, 2026Quarterly Revenue Growth
-91.40%vs Biotechnology peers
Gross Profit (TTM)
563.52MEUR658.34M · vs all stocks (USD)
EBITDA (TTM)
604.67MEUR706.41M · vs all stocks (USD)
Net Income (TTM)
487.93MEUR570.03M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-91.36%vs Biotechnology peers
Operating Cash Flow (TTM)
-301.60MEUR-352.35M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
210.97MEUR246.47M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.11BEURFY2025 · Dec 31, 2025Cost of Goods Sold
29.74MEURFY2025 · Dec 31, 2025Gross Profit
1.08BEURFY2025 · Dec 31, 2025Operating Income
501.39MEUR585.76M · vs all stocks (USD)
Pre-tax Income
300.87MEURFY2025 · Dec 31, 2025Income Tax Expense
-18.62MEURFY2025 · Dec 31, 2025Net Income
320.88MEURFY2025 · Dec 31, 2025EBIT
303.09MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
604.67MEURFY2025 · Dec 31, 2025Research & Development
459.42MEURFY2025 · Dec 31, 2025Selling, General & Administrative
111.96MEURFY2025 · Dec 31, 2025Other Operating Expenses
254.00KEURFY2025 · Dec 31, 2025Non-operating Interest Income
46.34MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
2.22MEURFY2025 · Dec 31, 2025EPS (Basic)
4.87EURFY2025 · Dec 31, 2025EPS (Diluted)
4.87EURFY2025 · Dec 31, 2025Basic Shares Outstanding
65.90MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
65.90MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
320.88MEURFY2025 · Dec 31, 2025Operating Cash Flow
-594.79MEURFY2025 · Dec 31, 2025Free Cash Flow
-608.03MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
87.87MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
320.88MEURFY2025 · Dec 31, 2025Depreciation & Amortization
55.88MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
-18.14MEURFY2025 · Dec 31, 2025Stock-based Compensation
24.00MEURFY2025 · Dec 31, 2025Other Non-cash Items
-100.84MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
86.59MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-963.16MEURFY2025 · Dec 31, 2025Capital Expenditures
-13.24MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-155.00KEURFY2025 · Dec 31, 2025Net Acquisitions
19.43MEURFY2025 · Dec 31, 2025Purchase of Investments
-3.47BEURFY2025 · Dec 31, 2025Sale of Investments
3.71BEURFY2025 · Dec 31, 2025Other Investing Activity
-20.00MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
228.52MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-3.27MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
-3.27MEURFY2025 · Dec 31, 2025Shares Outstanding
65.90MSharesUpdated Aug 21, 2026Float Shares
44.52MSharesUpdated Aug 21, 2026% Held by Insiders
25.36%vs all stocks
% Held by Institutions
32.44%vs all stocks
Total Cash (MRQ)
2.98BEUR3.48B · vs all stocks (USD)
Total Cash per Share (MRQ)
45.27EURUpdated Aug 21, 2026Total Debt (MRQ)
6.43MEUR7.52M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0020xvs Biotechnology peers
Current Ratio (MRQ)
30.48xvs Biotechnology peers
Book Value per Share (MRQ)
49.10EURUpdated Aug 21, 2026Total Assets
3.41BEUR3.98B · vs all stocks (USD)
Total Current Assets
3.08BEURFY2025 · Dec 31, 2025Total Liabilities
170.65MEURFY2025 · Dec 31, 2025Total Non-current Assets
327.06MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
17.79MEURFY2025 · Dec 31, 2025Total Current Liabilities
152.86MEURFY2025 · Dec 31, 2025Cash
87.87MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
87.87MEURFY2025 · Dec 31, 2025Other Short-term Investments
2.91BEURFY2025 · Dec 31, 2025Accounts Receivable
9.57MEURFY2025 · Dec 31, 2025Inventory
22.49MEURFY2025 · Dec 31, 2025Accounts Payable
32.62MEURFY2025 · Dec 31, 2025Short-term Debt
1.73MEURFY2025 · Dec 31, 2025Deferred Revenue
32.00KEURFY2025 · Dec 31, 2025Other Current Liabilities
38.90MEURFY2025 · Dec 31, 2025Long-term Debt
5.19MEURFY2025 · Dec 31, 2025Other Non-current Liabilities
12.60MEURFY2025 · Dec 31, 2025Common Stock (Book)
293.94MEURFY2025 · Dec 31, 2025Retained Earnings
210.58MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
3.24BEUR3.78B · vs all stocks (USD)
52-Week Low
22.32EURUpdated Aug 21, 202652-Week High
32.74EURUpdated Aug 21, 202652-Week Change
-9.84%vs all stocks
50-Day MA
25.53EURUpdated Aug 21, 2026200-Day MA
27.38EURUpdated Aug 21, 2026Avg 10-Day Volume
76.28KSharesUpdated Aug 21, 2026Avg 30-Day Volume
80.75KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
7.41EURUpdated Aug 21, 2026Other Income / Expense
-245.71MEURFY2025 · Dec 31, 202511 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
How is this stock valued?
Down-Close Streak With Profitability
A run of down weeks on a company profitable three years running and funded by equity.
Reads
Inverted P/B With Liquidity And Equity Ratio
It trades below book value, with current assets ample and the balance sheet equity-funded.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 46.8%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 0.47Industry median: -0.46Industry P95: 0.43Peers compared: 261
Current ratio is 30.48×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 30.48Industry median: 5.64Industry P95: 23.02Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
P/E ratio is 3.18×, lower than 95% of its Biotechnology peers (median 32.39×)Notable
P/E ratio: 3.18Industry median: 32.39Industry P5: 5.49Peers compared: 261
Price-to-book is 0.48×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.48Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 570,030,279.406Operating Cash Flow (USD, TTM): -352,346,057.086
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -1.68
Altman Z-Score 7.75: safe zoneNotable
Altman Z-Score: 7.75
High structural barrier to entryNotable
Barrier to Entry: 0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.92B, above the global median of $1.15BNotable
Market cap (USD): 1,918,464,010.814Global Median: 1,146,734,693.424
Revenue is $1.22B, above the global median of $520.53MNotable
Revenue (USD): 1,219,373,711.52Global Median: 520,528,949.311
Levered free cash flow is $246.47M, above the global median of $16.24MNotable
Levered free cash flow (USD): 246,468,391.657Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Aosaikang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Amylyx Pharmaceuticals, Inc. Common Stock
Tier 1ProductionApproval-Gated PipelineRule
Hugel Inc.
Tier 1ProductionApproval-Gated PipelineRule
ChemoMetec A/S
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harmony Biosciences Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Donghua Testing Technology Co., Ltd.
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And EquityLow-Leverage Liquidity Configuration
Hangzhou Sunrise Technology Co., Ltd.
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And EquityHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-DecelerationLow-Leverage Liquidity Configuration
Amoy Diagnostics Co., Ltd.
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And EquityLow-Leverage Liquidity Configuration